Oncology Excellence Sector
Each year, the Bordeaux Convention Bureau highlights the sectors of excellence in the region through video reports. With the aim of supporting the candidacy of major congresses, the Bordeaux Convention Bureau wishes to become more involved by supporting the sectors of excellence of the region. This third upcoming video report will focus on oncology sector of excellence and the Bergonié Institute.
Whether in clinical, technological, biological, epidemiological research or even in the human and social sciences, the Institut Bergonié works every day to further medicine, and more particularly oncology. It helps to enrich the ecosystem that has been created between hospitals, laboratories, and companies established in the region, which participates in developing this sector of excellence.
“Alongside cardiology and neurology or neurosciences, oncology is a discipline that is gaining importance in Bordeaux. An institutional and political wish to make oncology a sector of excellence has emerged in recent years. Bordeaux's strength is the large number of patients in the greater Aquitaine region (almost six million inhabitants). The population area covers a large territory, where the city of Bordeaux occupies a central place. This epicenter effect has been reinforced since the end of 2015 with the creation of new regions in France. Bordeaux oncology obtained a label of excellence from the National Cancer Institute (INCA) with the officialization of an Integrated Cancer Research Site (SIRIC) which was renewed in 2017. There are only 8 of them in France, half of which in the provinces.
The Institut Bergonié, only Cancer Treatment Center or Unicancer Center, in Nouvelle-Aquitaine, is located in the city center and plays an important role in cancer treatment with the Bordeaux University Hospital. Research activity is essential by collaborating with public scientific and technological establishments (EPST), such as INSERM, CNRS and the University of Bordeaux. The Health Cooperation Group signed in the beginning of 2016 between the CHU and the Institut Bergonié and encouraged by the Regional Health Agency, has for mission to give a synergistic drive to the development of innovation for cancer patients. The other two University Hospital of Nouvelle Aquitaine, Limoges and Poitiers, are not to be outdone and play a key role in the territorial network. Several biotechnology companies have realized the importance of the Bordeaux site and have come to establish themselves in the metropolis. In the age of videoconferences and “e-learning”, scientific communication by direct exchange remains essential to transform and validate exchanges between highly specialized teams in a given field. Numerous national and international cancer conferences have been organized in recent years and are planned for the next decade."
Professor François-Xavier MAHON, Director General of the Institut Bergonié
